Hsbc Holdings PLC Sells 59,379 Shares of Insulet Corporation $PODD

Hsbc Holdings PLC trimmed its position in shares of Insulet Corporation (NASDAQ:PODD) by 32.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 124,514 shares of the medical instruments supplier’s stock after selling 59,379 shares during the quarter. Hsbc Holdings PLC’s holdings in Insulet were worth $35,424,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. NewEdge Advisors LLC boosted its position in Insulet by 44.8% during the 1st quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier’s stock worth $54,000 after buying an additional 64 shares during the period. Cresset Asset Management LLC lifted its holdings in shares of Insulet by 7.3% during the second quarter. Cresset Asset Management LLC now owns 2,587 shares of the medical instruments supplier’s stock worth $813,000 after purchasing an additional 177 shares during the period. Cerity Partners LLC grew its stake in shares of Insulet by 68.7% in the second quarter. Cerity Partners LLC now owns 17,262 shares of the medical instruments supplier’s stock worth $5,423,000 after purchasing an additional 7,030 shares during the last quarter. Sei Investments Co. grew its stake in shares of Insulet by 27.4% in the second quarter. Sei Investments Co. now owns 137,643 shares of the medical instruments supplier’s stock worth $43,245,000 after purchasing an additional 29,584 shares during the last quarter. Finally, Treasurer of the State of North Carolina grew its stake in shares of Insulet by 2.5% in the second quarter. Treasurer of the State of North Carolina now owns 32,752 shares of the medical instruments supplier’s stock worth $10,290,000 after purchasing an additional 791 shares during the last quarter.

Insider Buying and Selling

In related news, Director Timothy C. Stonesifer acquired 2,790 shares of the stock in a transaction dated Wednesday, June 3rd. The stock was purchased at an average cost of $143.51 per share, with a total value of $400,392.90. Following the completion of the purchase, the director directly owned 9,041 shares in the company, valued at $1,297,473.91. This trade represents a 44.63% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.36% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. The Goldman Sachs Group reissued a “buy” rating and issued a $205.00 price target on shares of Insulet in a research note on Wednesday, May 27th. Wall Street Zen raised Insulet from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Jefferies Financial Group lowered their target price on Insulet from $400.00 to $360.00 in a report on Thursday, May 7th. Benchmark reissued a “buy” rating on shares of Insulet in a research note on Wednesday, May 27th. Finally, Barclays cut their price target on Insulet from $286.00 to $198.00 and set an “underweight” rating on the stock in a report on Thursday, May 7th. Twenty-two investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $238.67.

Insulet Stock Up 3.5%

Shares of NASDAQ PODD opened at $143.90 on Wednesday. The stock has a market capitalization of $9.97 billion, a P/E ratio of 33.47, a P/E/G ratio of 1.09 and a beta of 1.13. The company has a 50-day moving average price of $161.91 and a 200-day moving average price of $223.32. Insulet Corporation has a 1 year low of $138.79 and a 1 year high of $354.88. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81.

Insulet (NASDAQ:PODD) last posted its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The company had revenue of $761.70 million for the quarter, compared to analyst estimates of $729.89 million. During the same quarter in the prior year, the business posted $1.02 EPS. The firm’s revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, equities research analysts forecast that Insulet Corporation will post 6.46 EPS for the current fiscal year.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.